| Domain | Finding | Evidence type/year | Confidence / limitation | Suggested ontology terms |
|---|---|---|---|---|
| Disease identity | Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (CAASDS); **OMIM 614195**; **MONDO:0013618** | Aggregated disease-resource annotation; current Open Targets/MONDO mapping | Disease entity is recognized, but its human evidence base is extremely limited and anchored to the original report (PMID 15051220) (pqac-00000001, pqac-00000008) | **MONDO:** craniofacial anomalies and anterior segment dysgenesis syndrome; **OMIM:** 614195 |
| Causal-gene association | **VSX1** (visual system homeobox 1; RINX; ENSG00000100987) is the principal gene associated with CAASDS | Human genetic literature and database aggregation; 2004/current | Moderate database-level association; repeated records trace largely to the same publication rather than independent families (pqac-00000001, pqac-00000008) | **Suggested:** VSX1; visual system homeobox 1; DNA-binding transcription factor |
| Reported variant | **VSX1 p.Ala256Ser (A256S)**, a missense change reported in the conserved **CVC domain** | Human pedigree/case report, 2004; variant database record RCV000005562 | Disease-defining candidate, but no retrieved validated A256S-specific functional assay; modern literature notes uncertainty surrounding pathogenicity of reported VSX1 CVC variants (pqac-00000005, pqac-00000008) | **Suggested SO:** missense variant; germline variant; **suggested protein region:** CVC domain |
| Inheritance | Database annotation supports a **monoallelic**, autosomal or pseudoautosomal, non-imprinted requirement—consistent with reported autosomal-dominant inheritance | Human segregation/database annotation; 2004/current | Penetrance, phenocopies, de novo status, germline mosaicism, and recurrence risk were not established in the retrieved evidence; Genomics England confidence is “amber” (pqac-00000001, pqac-00000008) | **Suggested HPO:** Autosomal dominant inheritance |
| Craniofacial phenotype | Craniofacial anomalies were reported as part of the defining clinical presentation | Human clinical report, 2004 | Reported in a very small pedigree/case series; exact frequency, onset, severity, and progression cannot be generalized (pqac-00000004, pqac-00000011) | **Suggested HPO:** Craniofacial dysmorphism; Abnormality of facial morphology |
| Anterior ocular phenotype | Anterior-segment involvement included **corneal endothelial changes**, supporting the “anterior segment dysgenesis” designation | Human ophthalmic evaluation, 2004 | Specific laterality, quantitative endothelial findings, progression, and visual impact are not available in the retrieved excerpts (pqac-00000004, pqac-00000011) | **Suggested HPO:** Anterior segment dysgenesis; Abnormal corneal endothelium; Corneal abnormality |
| Sellar phenotype | **Empty sella** was reported | Human clinical/imaging report, 2004 | Evidence derives from the original report; endocrine consequences and penetrance are unknown (pqac-00000004, pqac-00000011) | **Suggested HPO:** Empty sella |
| Retinal physiology | Abnormal retinal bipolar-cell physiology/electroretinographic findings were reported; VSX1 is normally restricted to subsets of differentiated cone bipolar cells in mammals | Human electrophysiology plus comparative biology; 2004/2023 | Supports biological plausibility but does not prove that A256S caused the physiological abnormality (pqac-00000003, pqac-00000009) | **Suggested HPO:** Abnormal electroretinogram; Visual impairment; **suggested CL:** retinal bipolar neuron; cone retinal bipolar cell |
| Auditory physiology | Abnormal auditory bipolar-cell physiology was reported in the defining study | Human auditory electrophysiology; 2004 | Exact test results, clinical hearing threshold, penetrance, and natural history were not retrievable; “auditory bipolar cell” should not be conflated with retinal bipolar neurons (pqac-00000004, pqac-00000011) | **Suggested HPO:** Abnormal auditory electrophysiology; Hearing impairment |
| Mechanistic interpretation | A256S is hypothesized to alter CVC-assisted DNA binding and transcriptional regulation, potentially disturbing developmental cell-fate programs | Domain-based inference from VSX-family biology | **Inferred, not demonstrated for VSX1 A256S.** Experimental CVC-domain effects were shown principally for **VSX2**, which must not be treated as direct CAASDS evidence (pqac-00000005, pqac-00000006) | **Suggested GO:** DNA-binding transcription-factor activity; regulation of transcription by RNA polymerase II; cell-fate specification; retinal development |
| 2023 model evidence | Zebrafish **vsx1/vsx2 double knockout** caused severe visual impairment, bipolar-cell depletion, and precursor rerouting toward photoreceptor or Müller-glial fates, while neural-retina specification persisted without microphthalmia | CRISPR double-knockout zebrafish; electrophysiology, histology, RNA-seq, and ATAC-seq; 2023 | Strong comparative evidence for redundant VSX functions, but not a VSX1-only or A256S knock-in model and not a model of the craniofacial/sellar phenotype (pqac-00000009, pqac-00000010) | **Suggested GO:** retinal bipolar-cell differentiation; neural-retina development; cell-fate commitment; **suggested CL:** retinal bipolar neuron, photoreceptor cell, Müller glial cell |
| 2023 molecular profiling | Double-mutant zebrafish had **1,564** differentially accessible chromatin regions, but only **5%** of neighboring genes were differentially expressed, indicating network robustness | ATAC-seq, RNA-seq, and qPCR; 2023 | Quantitative model-organism result; cannot be assigned directly to human VSX1 A256S or craniofacial tissues (pqac-00000002, pqac-00000010) | **Suggested GO:** chromatin organization; regulation of gene expression; retinal development |
| Epidemiology | No population prevalence, incidence, carrier frequency, sex ratio, geographic distribution, or founder effect has been established | Negative evidence assessment | CAASDS appears ultra-rare, but a numerical prevalence cannot be calculated reliably from one defining report | **Suggested:** Rare disease; prevalence unknown |
| Treatment and trials | No disease-modifying therapy, genotype-directed treatment, registered CAASDS-specific clinical trial, or validated treatment algorithm was identified | Trial/resource search; current | Management must be phenotype-directed; absence of identified trials is not proof that none exist in every registry | **Suggested NCIT:** Supportive care; Ophthalmologic examination; Hearing assessment; Genetic counseling |
| Functional-validation gap | No retrieved study directly validated A256S effects on VSX1 protein stability, localization, DNA binding, transcriptional activity, or developmental phenotype | Evidence-gap assessment | Central limitation for ACMG/AMP interpretation; VSX2 experiments and vsx1/vsx2 double knockouts provide only indirect support (pqac-00000005, pqac-00000009) | **Suggested assay concepts:** DNA-binding assay; transcriptional-reporter assay; protein-localization assay; knock-in disease model |


*Table: This table maps the sparse human and model-organism evidence for CAASDS to suggested ontology concepts. It highlights the major limitations: dependence on one defining human report, uncertain A256S functional evidence, and lack of epidemiologic or therapeutic studies.*